Integrative network toxicology and experimental validation reveal novel molecular mediators of omeprazole-induced

Qian Huang1, Yuqian Li2, Zhiliang Gao3

  • 1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China; Department of Pharmacy, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

PubMed

Insights

Omeprazole may harm kidneys by affecting cell viability and increasing apoptosis, impacting key pathways like PI3K-Akt. This study identifies potential mechanisms and targets for preventing omeprazole-induced kidney injury.

Area of Science:

  • Pharmacology
  • Toxicology
  • Molecular Biology

Background:

  • Omeprazole, a proton pump inhibitor, is linked to adverse renal outcomes like acute kidney injury (AKI) and chronic kidney disease (CKD).
  • The precise mechanisms of omeprazole-induced nephrotoxicity are not fully understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms of omeprazole-induced renal toxicity.
  • To identify potential biomarkers and therapeutic targets for mitigating kidney injury associated with omeprazole use.

Main Methods:

  • An integrative network toxicology approach was employed.
  • Molecular docking and in vitro validation using HK-2 cells were performed.
  • Gene expression analysis (qPCR) was conducted to assess target upregulation.

Main Results:

  • 73 overlapping genes between omeprazole and kidney injury were identified, enriched in PI3K-Akt signaling and xenobiotic response pathways.
  • Six hub targets (CASP3, CCND1, EGFR, MMP9, PARP1, PPARG) showed strong binding affinity to omeprazole.
  • Omeprazole reduced cell viability, caused damage, and increased apoptosis in HK-2 cells, with specific gene expression changes observed.

Conclusions:

  • Omeprazole exposure can lead to renal toxicity through mechanisms involving key signaling pathways and cellular damage.
  • Identified hub targets and pathways offer potential avenues for developing strategies to prevent omeprazole-associated nephrotoxicity.

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
329
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
527
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
844
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
904
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
254
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.5K